LAUSR

ent from score 2 (21/47, 45%; P = 0.023) and 4 (24/27, 89%; P = 0.030), we categorized patients into 3 groups: Deauville score 1– 2, 3, and 4–5. With a median follow‐up of 54.7 months (IQR, 30.2–84.5), 5‐year PFS rate was 35.7% (95% CI, 30.0–41.4), and OS rate was 47.1% (95% CI, 40.8–53.4). NCCN‐IPI risk and post‐treatment PET‐CT scan were independently associated with PFS in multivariate analysis (for LI NCCN‐IPI, hazard ratio [HR] 1.615, 95% CI 0.838–3.113; HI NCCN‐ IPI, HR 3.063, 95% CI 1.626–5.769; high NCCN‐IPI 4.475, 95% CI 2.231–8.977; P < 0.001: for post‐treatment Deauville score 3, HR 1.895, 95% CI 1.281–2.801; score 4–5, HR 6.916, 95% CI 4.948– 9.667; P < 0.001). We stratified patients into 5 groups based on risk of progression: low (low NCCN‐IPI and Deauville score 1–2), INT‐1 (low NCCN‐IPI and score 3, or LI NCCN‐IPI and score 1–2), INT‐2 (HI NCCN‐IPI and score 1–2), high (high NCCN‐IPI and score 1–2, or LI to high NCCN‐IPI and score 3), and very high (score 4–5). The risk model showed a strong association with PFS and OS (Figure 1). Conclusion: This study proposes a new risk stratification model incorporating baseline NCCN‐IPI in combination with post‐treatment Deauville score on PET‐CT scan in patients with newly diagnosed nodal PTCL.